Bajaj Healthcare Ltd
BAJAJHCAREBajaj Healthcare Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: profits are rising, but only 59% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a downtrend (51 weeks in) while the P/E sits at the 45th percentile of its own 10-year range. Underneath, the last four quarters read improving — profit +16.7% year on year, and 59% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Bajaj Healthcare Ltd trades at ₹374, in a downtrend and 51 weeks into that stage. That is +2.5% against its own 200-day average. It sits at 45% of a 52-week range of ₹284 to ₹484. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 2 straight weeks.
Today the stock is in a downtrend — week 51 of stage 4, confirmed. At ₹374 it trades +2.5% versus its 200-day average and sits at 45% of its 52-week range (₹284–₹484).
Against the market, two honest reads. Cumulative: over the last 10.2 years the stock moved +765% while the NIFTY 500 moved +252% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 2 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 45th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Bajaj Healthcare Ltd trades at 19.3× P/E, mid-range by its own standards (45th percentile). Its long-run median P/E is 20.1×, measured across 10.2 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 19.3× is mid-range by its own standards (45th percentile), against a long-run median of 20.1× measured over 10.2 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −62.6% against a −28.5% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the −4.0%/yr price move, ~−10.5%/yr came from earnings growth and ~+6.5 pp from the multiple (expanding); over 10y, of the +24.0%/yr price move, ~+7.5%/yr came from earnings growth and ~+16.5 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Bajaj Healthcare Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 8 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +12.5% | −1.8% | −1.4% | +10.6% |
| Profit | −60.0% | −28.1% | −28.1% | +7.2% |
| EPS | −62.6% | −33.0% | −31.1% | +4.4% |
| Share price | −28.5% | +6.3% | −4.0% | +24.0% |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
38.2/100 — rank 37 of 43 in Pharma - Formulators · 87% evidence confidence
Bajaj Healthcare Ltd scores 38.2 out of 100 against the 43 companies it is compared with in Pharma - Formulators, ranking 37. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 10.1 + 10.4 + 11 + 6.7 = 38.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Bajaj Healthcare Ltd reported ₹166 Cr of revenue in the Jun 26 quarter, +11.4% year on year. Over 10 years it has compounded at 10.6% a year. The last full year, FY26, came in at ₹611 Cr. The last four reported quarters add to ₹628 Cr.
Bajaj Healthcare Ltd reported ₹166 Cr of revenue in the Jun 26 quarter, +11.4% year on year. Over 10 years it has compounded at 10.6% a year. The last full year, FY26, came in at ₹611 Cr. The last four reported quarters add to ₹628 Cr.
FY26 revenue came in at ₹611 Cr (+12.5% on the year), capping 10 years at 10.6% compound. The latest quarter (Jun 26) printed ₹166 Cr, +11.4% year on year.
Pace check: the last four quarters averaged +13.3% growth against the decade's 10.6% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +12.3% over the last 4 quarters against +14.9%/yr over the last 8 — stabilising.
→ Revenue grew — did margins hold as it scaled? Next: 17.0% this quarter (+1.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Bajaj Healthcare Ltd's operating margin is 17.0% in the Jun 26 quarter, +1.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 9.0% to 21.0%. The current quarter sits inside that band.
Bajaj Healthcare Ltd's operating margin is 17.0% in the Jun 26 quarter, +1.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 9.0% to 21.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 17.0%, +1.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 9.0%–21.0%.
Why the margin moved: operating margin went +0.9 pp year on year while gross margin went +2.2 pp — the gain came mostly from the gross line: input costs and pricing.
→ Margins held — did that reach the bottom line? Next: profit +16.7% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Bajaj Healthcare Ltd earned ₹14.0 Cr of net profit in the Jun 26 quarter, +16.7% year on year. Full-year FY26 profit was ₹16.0 Cr. The 10-year compound rate is 7.2%. That is 8.4% of the quarter's revenue. The same quarter a year earlier earned ₹12.0 Cr. 4 of the last 12 reported quarters were loss-making.
Bajaj Healthcare Ltd earned ₹14.0 Cr of net profit in the Jun 26 quarter, +16.7% year on year. Full-year FY26 profit was ₹16.0 Cr. The 10-year compound rate is 7.2%. That is 8.4% of the quarter's revenue. The same quarter a year earlier earned ₹12.0 Cr. 4 of the last 12 reported quarters were loss-making.
Jun 26 profit was ₹14.0 Cr, +16.7% year on year. On the full year, FY26 printed ₹16.0 Cr (−60.0%), and the 10-year compound rate is 7.2%.
Why profit moved: revenue contributed +11.4% and the margin +1.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit −59.2% vs revenue +13.3%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
→ Profit rose — but did the cash follow? Next: 59% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 59% of Bajaj Healthcare Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹58.0 Cr of operating cash against ₹16.0 Cr of profit. After ₹43.0 Cr of capital spending, ₹15.0 Cr was left as free cash.
FY26: operating cash of ₹58.0 Cr against reported profit of ₹16.0 Cr, leaving free cash of ₹15.0 Cr after ₹43.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 59% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 59%: the cash cycle stretched 174 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 174 days — the next section's job is to find where the cash is stuck.
→ So follow the cash to where it goes. Next: the 256-day cycle, in money terms.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Bajaj Healthcare Ltd's cash conversion cycle runs 256 days in FY26, up from 82 days in FY21. Capital spending ran ₹−48.0 Cr over the last 3 years. At FY26 sales of ₹611 Cr each day of that cycle holds about ₹1.7 Cr, so roughly ₹429 Cr sits inside the business at any moment.
FY26: debtors at 140 days, inventory at 249 days — roughly 8.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 256 days, looser than FY21's 82.
The full loop: cash goes out to suppliers and production on day 0; stock waits 249 days to sell; customers pay about 140 days after that; and suppliers themselves are paid at 133 days — netting out to the 256-day cycle.
In money terms: at FY26 sales of ₹611 Cr, each day of the cycle holds about ₹1.7 Cr — so the 256-day loop keeps roughly ₹429 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹−48.0 Cr over the last 3 fiscal years against ₹84.0 Cr of depreciation — spending at or below maintenance level. Capital work-in-progress stands at ₹8.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 11% and the ROIC − WACC spread is −4.2 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Bajaj Healthcare Ltd earns a ROCE of 11% in FY26. That is up from a trough of 8% in FY24. Return on invested capital clears the cost of that capital by −4.2 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 2.6% net margin on 0.66× asset turns.
FY26 ROCE is 11%, recovered from a FY24 trough of 8% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 2.6% net margin × 0.66× asset turns × 1.73× balance-sheet leverage ≈ 3.0% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 7.8% − 12.0% = a −4.2 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.47.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Bajaj Healthcare Ltd carries total debt of ₹249 Cr against shareholder equity of ₹533 Cr as of Jun 26, a debt-to-equity of 0.47. On the annual view that ratio went from 0.78 in FY22 to 0.47 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Jun 26: total debt of ₹249 Cr against shareholder equity of ₹533 Cr — a debt-to-equity of 0.47. On the annual view, debt-to-equity went from 0.78 (FY22) to 0.47 (FY26). Read the returns on this page with that leverage in mind.
→ Who owns this, and are they adding or leaving? Next: Promoters cut 9.1 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters cut 9.1 points of Bajaj Healthcare Ltd over 8 quarters, the biggest move on the register. That takes promoters to 58.6% of the company. Foreign institutions moved +2.2 points over the same window, to 2.2%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: −9.1 points over 8 quarters to 58.6%; Foreign institutions: +2.2 points over 8 quarters to 2.2%; Domestic institutions: +1.9 points over 8 quarters to 1.9%.
🚨 Why the register moved: promoters drove it (−9.1 points), absorbed on the other side by foreign institutions (+2.2 points) — distribution into the market’s bid.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Bajaj Healthcare Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Bajaj Healthcare Ltd this page | 19.3× | ₹1,088 Cr | No read | |||
| Sun Pharmaceutical Industries Ltd | 37.5× | ₹4.7L Cr | Improving | |||
| Torrent Pharmaceuticals Ltd | 86.1× | ₹1.9L Cr | Consistent | |||
| Cipla Ltd | 31.8× | ₹1.1L Cr | Deteriorating | |||
| Zydus Lifesciences Ltd | 20.4× | ₹1.1L Cr | Consistent | |||
| Lupin Ltd | 19.1× | ₹1.1L Cr | Consistent | |||
| Mankind Pharma Ltd | 51.4× | ₹1L Cr | Turning around | |||
| Dr Reddys Laboratories Ltd | 29.8× | ₹96,130 Cr | Deteriorating | |||
| Aurobindo Pharma Ltd | 25.1× | ₹88,979 Cr | Mixed | |||
| Biocon Ltd | 182.0× | ₹70,672 Cr | Deteriorating | |||
| Alkem Laboratories Ltd | 27.6× | ₹67,357 Cr | Mixed | |||
| Glenmark Pharmaceuticals Ltd | 21.0× | ₹61,858 Cr | No read | |||
| Ipca Laboratories Ltd | 37.9× | ₹44,720 Cr | Consistent | |||
| Ajanta Pharma Ltd | 37.3× | ₹42,097 Cr | Consistent | |||
| J B Chemicals & Pharmaceuticals Ltd | 53.8× | ₹38,677 Cr | Topping out | |||
| Emcure Pharmaceuticals Ltd | 37.7× | ₹35,679 Cr | Mixed | |||
| Wockhardt Ltd | 106.0× | ₹30,048 Cr | No read | |||
| Rubicon Research Ltd | 102.0× | ₹25,141 Cr | No read | |||
| ERIS Lifesciences Ltd | 30.7× | ₹19,409 Cr | Turning around | |||
| Caplin Point Laboratories Ltd | 29.2× | ₹18,753 Cr | Consistent | |||
| Natco Pharma Ltd | 11.6× | ₹16,504 Cr | Topping out | |||
| Alembic Pharmaceuticals Ltd | 21.4× | ₹15,678 Cr | Turning around | |||
| Corona Remedies Ltd | 64.7× | ₹12,923 Cr | No read | |||
| Marksans Pharma Ltd | 26.7× | ₹11,161 Cr | Consistent | |||
| Akums Drugs & Pharmaceuticals Ltd | 40.3× | ₹10,818 Cr | No read | |||
| Strides Pharma Science Ltd | 16.6× | ₹9,402 Cr | No read | |||
| Suven Life Sciences Ltd | — | ₹8,929 Cr | No read | |||
| FDC Ltd | 22.6× | ₹6,723 Cr | Turning around | |||
| Bliss GVS Pharma Ltd | 37.4× | ₹4,927 Cr | Turning around | |||
| RPG Life Sciences Ltd | 44.3× | ₹4,858 Cr | — | — | — | — |
| Gufic BioSciences Ltd | 59.2× | ₹3,799 Cr | No read | |||
| Kwality Pharmaceuticals Ltd | 42.5× | ₹2,886 Cr | Consistent | |||
| Kwality Pharmaceuticals Ltd | 36.6× | ₹2,483 Cr | Consistent | |||
| Sai Parenterals Ltd | 166.0× | ₹2,366 Cr | — | — | — | — |
| Indoco Remedies Ltd | — | ₹2,247 Cr | No read | |||
| Fredun Pharmaceuticals Ltd | 45.4× | ₹1,480 Cr | — | No read | ||
| Amrutanjan Health Care Ltd | 22.8× | ₹1,472 Cr | Mixed | |||
| Accent Microcell Ltd | 27.1× | ₹1,187 Cr | No read | |||
| Lincoln Pharmaceuticals Ltd | 13.2× | ₹1,162 Cr | Turning around | |||
| Bharat Parenterals Ltd | — | ₹990 Cr | No read |
Frequently asked questions
What is Bajaj Healthcare Ltd's share price today?
Bajaj Healthcare Ltd trades at ₹374, −28.5% over the past year. The company is valued at ₹1,088 Cr. The stock sits at 45% of its 52-week range of ₹284–₹484, +2.5% versus its 200-day average. On the tape, the price is in a downtrend, 51 weeks in. — as of 24 July 2026.
What were Bajaj Healthcare Ltd's latest quarterly results?
Bajaj Healthcare Ltd reported revenue of ₹166 Cr and net profit of ₹14.0 Cr for the Jun 26 quarter. Revenue rose 11.4% and profit rose 16.7% year on year. Earnings per share were ₹4.07. The operating margin was 17.0%, 1.0 pp higher than a year earlier. — as of 24 July 2026.
What is Bajaj Healthcare Ltd's revenue?
Bajaj Healthcare Ltd reported revenue of ₹166 Cr in the Jun 26 quarter, +11.4% year on year. For the full FY26 fiscal year, revenue was ₹611 Cr (+12.5%). Over the last 10 years revenue compounded at 10.6% a year. — as of 24 July 2026.
What is Bajaj Healthcare Ltd's profit?
Bajaj Healthcare Ltd earned ₹14.0 Cr of net profit in the Jun 26 quarter, +16.7% year on year. Full-year FY26 profit was ₹16.0 Cr. The operating margin ran 17.0% in the latest quarter. — as of 24 July 2026.
What is Bajaj Healthcare Ltd's market cap?
Bajaj Healthcare Ltd's market capitalisation is ₹1,088 Cr at a share price of ₹374. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Bajaj Healthcare Ltd's P/E ratio?
Bajaj Healthcare Ltd trades at a P/E of 19.3×, at the 45th percentile of its own 10-year range, against a long-run median of 20.1×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Bajaj Healthcare Ltd pay a dividend?
Yes — Bajaj Healthcare Ltd's dividend payout was 32% of profit in FY26, and it recorded a payout in 6 of its last 13 reported fiscal years. One of those years shows a negative ratio because profit itself was negative. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Bajaj Healthcare Ltd overvalued?
On its own history, Bajaj Healthcare Ltd looks mid-range against its own history: its P/E of 19.3× sits at the 45th percentile of its 10-year range (long-run median 20.1×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
Is Bajaj Healthcare Ltd growing?
Yes — Bajaj Healthcare Ltd is growing: latest-quarter revenue +11.4% year on year, profit +16.7%, and the margin +1.0 pp at 17.0%. The 10-year compound rates are 10.6% (revenue) and 7.2% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is Bajaj Healthcare Ltd performing?
Bajaj Healthcare Ltd is in a downtrend, 51 weeks in. Its latest quarter's revenue rose 11.4% and profit rose 16.7% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
Is Bajaj Healthcare Ltd in an uptrend?
No — the price is in a downtrend (week 51 of stage 4), trading +2.5% versus its 200-day average and at 45% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Bajaj Healthcare Ltd beating the market?
On recent form, yes — Bajaj Healthcare Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 2 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.2 years the stock moved +765% against the NIFTY 500's +252% — ahead of the index over the full window. — as of 24 July 2026.
Will Bajaj Healthcare Ltd's share price go up?
This page publishes no price forecast for Bajaj Healthcare Ltd. What it measures instead: the share price is ₹374, the price is in a downtrend 51 weeks in. Its P/E of 19.3× sits at the 45th percentile of its own 10-year range. — as of 24 July 2026.
Who owns Bajaj Healthcare Ltd?
Promoters hold 58.6% of Bajaj Healthcare Ltd, foreign institutions 2.2%, domestic institutions 1.9% and the public 37.3% (latest quarter). The biggest move on the register over the last two years: Promoters cut 9.1 points over 8 quarters. — as of 24 July 2026.
Does Bajaj Healthcare Ltd have too much debt?
It is moderate — Bajaj Healthcare Ltd's debt-to-equity is 0.47, and operating profit covers the interest bill 5×. FY26 borrowings were ₹249 Cr against equity of ₹533 Cr. Read the returns on this page with that leverage in mind — as of 24 July 2026.
What is Bajaj Healthcare Ltd's capex?
Bajaj Healthcare Ltd spent ₹−48.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹43.0 Cr, with ₹8.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Bajaj Healthcare Ltd's cash flow?
Bajaj Healthcare Ltd generated ₹58.0 Cr of operating cash flow in FY26 and ₹15.0 Cr of free cash flow after ₹43.0 Cr of capital spending. Reported profit that year was ₹16.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Bajaj Healthcare Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 59% of Bajaj Healthcare Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹58.0 Cr against reported profit of ₹16.0 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 24 July 2026.
Where is Bajaj Healthcare Ltd in its business cycle?
Bajaj Healthcare Ltd's FY26 operating margin was 17.0%, against a 13-year band of 9.0%–21.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 17.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Bajaj Healthcare Ltd story?
The sharpest disagreement: profits are rising, but only 59% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Bajaj Healthcare Ltd a stock worth studying right now?
This is not investment advice. The machine read: Bajaj Healthcare Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.